Quality of life matters in mCRPC
At #ESMO26, PR21 showed better patient-reported QoL with Lu-PSMA-617 vs docetaxel and no significant difference in rPFS.
An important consideration when choosing treatment sequence #DKhalaf @OncoAlert
256 views · 8 likes · 6 reposts · 0 replies
BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer
https://esmocongress.esmo.orgAnbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.org- **标题 / Title:** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.orgSource: Deborah Mukherji · x.com
